Patent Application
20160175271
(a) Field of the Invention
The present invention is directed to a rectal suppository comprising mesalamine and a corticosteroid designed to provide more therapeutically effective benefit for ulcerative colitis management. The invention is further directed to a method for manufacturing the suppository, and methods for treating ulcerative colitis, such as active ulcerative proctitis.
(b) Description of the Related Art
Inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis (UC), are characterized by chronic, relapsing intestinal inflammation. Crohn's disease and UC are believed to involve a dysregulated immune response to gastrointestinal (GI) tract antigens, a mucosal barrier breach, and/or an adverse inflammatory reaction to a persistent intestinal infection. In healthy individuals without IBD, the GI tract luminal contents and bacteria constantly stimulate the mucosal immune system, and a delicate balance of pro-inflammatory and anti-inflammatory cells and molecules maintains the integrity of the GI tract, without eliciting severe and damaging inflammation [MacDermott, R. P., J Gastroenterology, 31:907:-916 (1996)]. It is unknown how the IBD inflammatory cascade begins, but constant GI antigen-dependent stimulation of the mucosal and systemic immune systems perpetuates the inflammatory cascade and drives lesion formation.
UC is a non-specific inflammatory disease of the colon that is of unknown cause and is characterized by diarrhoea with discharge of mucus and blood, cramping abdominal pain, inflammation and edema of the mucous membrane with patches of ulceration. UC limited to the rectum is known as ulcerative proctitis. People suffering from chronic UC affecting the whole colon have an increased risk of colonic cancer. Furthermore, when medical therapy fails, surgical resection of affected bowel may be necessary.
In patients with more extensive disease, blood loss from the inflamed intestines can lead to anaemia, and may require treatment with iron supplements or even blood transfusions. Although infrequent, the colon can acutely dilate to a large size when the inflammation becomes very severe. This condition is called toxic megacolon. Patients with toxic megacolon are extremely ill with fever, abdominal pain and distention, dehydration, and malnutrition. Unless the patient improves rapidly with medication, surgery is usually necessary to prevent colon rupture and high risk of death.
The type and formulation of therapy recommended for patients with UC is dependent on both the location of the disease and the degree of severity. In some patients, the inflammation is limited to the rectum only (distal), but other affected individuals have colonic disease that extends along the length of much of the colon (extensive).
Mesalamine, 5-aminosalicylic acid (5-ASA), is used as a first-line treatment for patients with mild-to-moderate UC and is effective in reducing disease symptoms and the incidence of relapse in UC. While mesalamine is available in oral form, intrarectal administration of mesalamine has several advantages. For example, rectal administration of a drug avoids some side-effects, such as gastrointestinal disorders, due to oral administration. As mesalamine is a locally GI active drug, lower doses of the drug can be administered rectally to obtain a better or equivalent therapeutic effect as that attained with a higher dose oral formulation. The absorption of a drug orally administered may also be affected by whether it is administered before or after each meal or between meals. There is no such food effect when drugs are administered intrarectally. Advantageously, intrarectal administration can be performed even during periods of nausea, vomiting or unconsciousness, or even after a surgical procedure.
A mesalamine suppository is currently marketed in the United States by Aptalis Pharma as Canasa® for the treatment of active ulcerative proctitis.
U.S. Pat. No. 5,629,012 discloses a process of preparing a mesalamine suppository by preparing granulates of mesalamine, talc, magnesium stearate, polyvinyl pyrrolidone and polyethylene glycol and compressing the granulates in a tableting machine. The suppository contains 50-75% drug load. The patent further teaches to use polyethylene glycol base as it is critical to form a uniform and smooth suppository with such a high drug load.
U.S. Pat. Nos. 8,217,083 and 8,436,051 disclose a suppository with an oily or fatty base, mesalamine of a specific tap density, and a total drug load in the range of 35% to 50%.
U.S. Pat. No. 8,629,127 discloses an oral composition comprising a combination of mesalamine and N-acetylcysteine for the treatment of inflammatory bowel disease.
An advanced therapy with comparable or greater efficacy than existing ulcerative colitis therapies, but with a lower incidence of serious adverse reactions, would be still desirable for effective management of ulcerative colitis. There remains a need for novel and effective therapeutic options for management of UC that have few adverse effects, are well tolerated by patients and also provide comfort of use.
The present invention provides a rectal suppository comprising a combination of mesalamine and a corticosteroid. The suppository further comprises a suppository base, a surfactant and a mucoadhesive agent. The suppository has a relatively smaller size and provides better retention in the rectum for a long period of time. Further, the suppository also delivers a therapeutically effective amount of mesalamine for the ulcerative colitis therapy by reducing first pass metabolism of mesalamine. A method of treating ulcerative colitis with such suppository is further provided by the invention.
In one aspect, the invention provides a rectal suppository comprising mesalamine and at least one corticosteroid.
In another aspect, the invention provides a rectal suppository comprising mesalamine and at least one corticosteroid, a suppository base, at least one surfactant, and at least one mucoadhesive agent.
In another aspect, the invention provides a rectal suppository comprising mesalamine, at least one corticosteroid, a suppository base, at least one surfactant, and one or more mucoadhesive agents, wherein the suppository has a drug load ranging from 30% to 65%.
In another aspect, the invention provides a rectal suppository comprising mesalamine, at least one corticosteroid, a suppository base, at least one surfactant, and one or more mucoadhesive agents, wherein the suppository comprises from about 450 to about 2,000 mg of mesalamine.
In another aspect, the invention provides a rectal suppository comprising mesalamine, at least one corticosteroid, a suppository base, at least one surfactant, and one or more mucoadhesive agents, wherein the suppository comprises from about 0.5% w/w to about 5% w/w of mucoadhesive agent. In an embodiment, the suppository comprises from about 0.5% w/w to about 2% w/w of mucoadhesive agent.
In another aspect, the invention provides a rectal suppository comprising mesalamine, at least one corticosteroid, a suppository base, at least one surfactant, and one or more mucoadhesive agents, wherein the mesalamine has a mean particle size of less than 120 microns. In an embodiment, 50% of the total amount of the mesalamine has a mean particle size of less than 20 microns. In a further embodiment, 50% of the total amount of the mesalamine has a mean particle size of less than 100 microns.
In another aspect, the invention provides a method of manufacturing a rectal suppository, which process comprises the steps of:
Each step of addition involves mixing under low or high shear for a suitable period of time. The mixing during each step of addition can be performed for a period of 15 minutes to 2 hours. The sequence of addition steps can be interchangeable.
In another aspect, the invention provides a method of treating active ulcerative proctitis in a patient in need thereof comprising administering the rectal suppository as substantially described herein. In an embodiment, the rectal suppository is administered once a day for the treatment of active ulcerative proctitis.
Still other aspects and advantages of the invention will be apparent from the following detailed description of the invention.
The invention provides for a rectal suppository comprising a combination of mesalamine and a corticosteroid. The suppository further comprises a suppository base, at least one surfactant, and at least one mucoadhesive agent.
In another aspect, the invention provides for a rectal suppository consisting essentially of a combination of mesalamine and a corticosteroid as the active ingredients and pharmaceutical excipients that consist essentially of a suppository base, at least one surfactant, and at least one mucoadhesive agent to deliver the suppository with improved bioavailability and have a melting point that is less than about 37° C.
In another aspect, the invention provides for a rectal suppository consisting of a combination of mesalamine and a corticosteroid as the active ingredients and pharmaceutical excipients that consist of a suppository base, at least one surfactant, and at least one mucoadhesive agent to deliver the suppository with improved bioavailability and have a melting point that is less than about 37° C.
In another aspect, the invention provides for a rectal suppository consisting essentially of or consisting of a combination of mesalamine and a corticosteroid as the active ingredients and pharmaceutical excipients that include a suppository base, at least one surfactant, and at least one mucoadhesive agent to deliver the suppository with improved bioavailability and have a melting point that is less than about 37° C.
The inventors have found that the combination of mesalamine and corticosteroid agent, preferably when administered in the form of suppository, provided significant improvement in symptoms of UC.
Mesalamine undergoes rapid and extensive hepatic first-pass metabolism following oral administration. Currently approved suppositories of mesalamine contain a very high dose of the drug considering the demand for effective ulcerative colitis treatment. Rectal administration of mesalamine in such a high dose may result in a significant amount of the drug undergoing first pass metabolism. Further, it is considered advantageous to have a suppository of the size that is minimized to be as small as possible in order to ensure good patient compliance.
The inventors have found that the combination of surfactant, mucoadhesive agent and the base in the suppository improved rectal bioavailability of mesalamine as the mucoadhesive force increased. Retaining mesalamine at the dosed site in the rectum by the addition of the mucoadhesive appeared to be very important in avoiding first-pass hepatic elimination and increasing the bioavailability of mesalamine.
The inventors have further observed that use of two types of mesalamine particles differing in particle size is also advantageous to improve bioavailability. Further, by using mesalamine particles of two different sizes permits the size of the resulting suppository to be kept smaller than would otherwise be necessary.
The term “mesalamine”, as used herein, includes its base, pharmaceutically acceptable salts, optical isomers and racemic mixtures.
The term “drug load” refers to the weight percentage of mesalamine based on the total weight of the suppository.
The invention provides a rectal suppository comprising mesalamine and at least one corticosteroid. The invention also provides a rectal suppository comprising mesalamine, at least one corticosteroid, a suppository base, and at least one mucoadhesive agent.
Suitable corticosteroids that can be used in combination with mesalamine in accordance with the invention include betamethasone, methylprednisolone, prednisolone, hydrocortisone, cortisone, tixocortol, prednisone, mometasone, amcinonide, budesonide, desonide, betamethasone, dexamethasone, prednicarbate, fluocortolone, clobetasone, clobetasol, fluprednidene, clobetasol, halobetasol, diflorasone, fluocinonide, halcinonide, triamcinolone, desoximetasone, fluocinolone, flurandrenolide, fludrocortisone, fluticasone, desonide, prednicarbate, difluocortolone, deflazacort and salts or derivatives thereof. Preferred corticosteroids are budesonide, triamcinolone, hydrocortisone and fluticasone.
The amount of mesalamine in the suppository ranges from about 450 to about 2,000 mg of mesalamine.
The amount of corticosteroid in the suppository ranges from about 5 to about 100 mg of corticosteroid.
In embodiment, the suppository has a drug load ranging from about 30% to about 65%. In a further embodiment, the suppository has a drug load ranging from 50% to 65%.
In an embodiment, mesalamine particles have a mean particle size of less than 120 microns. Preferably, 30% to 60% of the total amount of the mesalamine has a mean particle size of less than 20 microns and 40% to 70% of the mesalamine has a mean particle size of less than 100 microns.
Suitable mucoadhesive agents, by way of example and without limitation, include polycarbophil, carbopol, sodium alginate, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, natural gums, lecithins, pectin, ammonia alginate, calcium alginate, potassium alginate, propylene glycol alginate, agar, gum arabic, gum karaya, locust bean gum, tragacanth, carrageenans, guar, xanthan, and scleroglucan, and mixtures thereof. Preferred mucoadhesive agents are selected from polycarbophil, carbopol, sodium alginate, and hydroxyethyl cellulose.
In an embodiment, the amount of mucoadhesive agent in the suppository is from about 0.5% w/w to about 5% w/w. Preferably the amount of mucoadhesive agent in the suppository is from about 0.5% w/w to about 2% w/w.
The suppository base can be an oily or fatty base. Conventional suppository bases which may be employed include theobroma oil, hard fats, glycerides of fatty acids, glycerol-gelatin bases, and mixtures thereof. Suitable hard fat bases include, but are not limited to, esterified mixtures of mono-, di- and triglycerides which are obtained by esterification of fatty acids (European Pharmacopoeia, 3rd edition 1997, Deutscher Apotheker Verlag Stuttgart. p. 1022; The United States Pharmacopoeia, USP 23, NF18). Such hard fats are commercially available, for example, under the name Witepsol™ (e.g. Witepsol™ H12 and H15). A preferred suppository base is hard fat (e.g., hard fat NF).
Preferred hard fat bases include, but are not limited to, hard fats containing a mixture of mono-, di- and triglycerides of saturated C9-18 fatty acids or the mixture of triglycerides, diglycerides and monoglycerides. It is a synthetic fat prepared by hydrogenating suitable vegetable oils. The hard fat base can comprise hard fats obtained by esterification of fatty acids of vegetable origin with glycerol, a macrogol ether containing 20 to 24 oxyethylene groups in the polyoxyethylene chain, e.g., polyoxyl-20-cetostearyl ether, and glycerides, e.g., glyceryl ricinoleate. A preferred hard fat is hydrogenated vegetable oil.
Other suitable suppository bases include, but are not limited to, cocoa butter, lauric oil, beef tallow, hard fat, and any combination of any of the foregoing.
In an embodiment, the suppository base is devoid of polyethylene glycol.
The suppository may further contain a surfactant to improve mesalamine dispersing into the oily or fatty base, to increase the spreading of the melted suppository on the rectal mucosa leading to a greater contact surface, and to reduce the viscosity of the molten mass and to reduce the pathway of drug particles to the interface.
Suitable surfactants, by way of example and without limitation, include disodium laurenth sulfosuccinate, polysorbates, polyoxyethylene derivatives of natural or hydrogenated vegetable oils such as castor oil; polyoxyethylene-sorbitan fatty acid esters, such as mono-, di- and tri-lauryl, palmityl, stearyl and oleyl esters; alkyl/dialykyl sulfate, sulfonate or sulfosuccinate salts such as sodium lauryl sulfate and dioctyl sodium sulfosuccinate; polyoxyethylene fatty acid esters; phospholipids such as lecithins; transesterification products of natural vegetable oil triglycerides and polyalkylene polyols; sorbitan fatty acid esters; pentaerythritol fatty acid esters; polyoxyethylene glycol alkyl ethers and esters; and the like.
Examples of specific surfactants which may be used include, without limitation, polyoxyethylene castor oil derivatives, such as polyoxyethylene glycerol triricinoleate polyoxyl 35 castor oil (CREMOPHOR® EL, available from BASF Corporation), and polyoxyl 40 hydrogenated castor oil (CREMOPHOR® RH40, available from BASF Corporation); mono-fatty acid esters of polyoxyethylene (20) sorbitan, such as polyoxyethylene (20) sorbitan monooleate (TWEEN® 80), polyoxyethylene (20) sorbitan monostearate (TWEEN® 60), polyoxyethylene (20) sorbitan monopalmitate (TWEEN® 40), and polyoxyethylene (20) sorbitan monolaurate (TWEEN® 20) (all available from ICI Surfactants, Wilmington, Del.); polyoxyethylene glycol 200 monostearate (MYRJ® 52, available from Calgene Chemicals, Skokie, Ill.); polyglycerol esters with a HLB of 10 or greater, such as decablyceryl mono- and dioleate and the like; and mixtures thereof.
The surfactant may comprise about 0.2% to 2% w/w of the suppository.
The invention further provides a method of manufacturing the rectal suppository of the invention comprising a matrix core. The process comprises the steps of:
Each step of addition involves mixing under low or high shear for a suitable period of time. The mixing during each step of addition can be performed for a period of 15 minutes to 2 hours. The sequence of addition steps can be interchangeable.
The total weight of the suppository preferably ranges from about 2,000 to about 3,000 mg. According to one embodiment, the suppository has a total weight of about 2,000 mg, about 2,500 mg or about 2,900 mg.
The suppository is preferably smooth and torpedo-shaped.
The melting point of the suppository is generally sufficient to melt in the patient's body, and is typically no more than about 37° C.
The suppository can be administered to treat ulcerative colitis, such as active ulcerative proctitis, in a patient in need thereof. Preferably, the suppository is administered in sufficient quantity and frequency to reduce the symptoms of ulcerative colitis.
The suppository can also be administered prophylactically to a patient at risk for ulcerative colitis (such as active ulcerative proctitis). Preferably, the suppository is administered in a sufficient quantity and frequency to delay or prevent the onset of symptoms of ulcerative colitis (e.g., to delay or prevent the onset of abdominal pain, diarrhea, rectal bleeding, weight loss, fever, loss of appetite, dehydration, anemia, or malnutrition, or any combination thereof).
In the above methods, the suppository is preferably administered once a day and more preferably once a day at bedtime. The suppository is also preferably retained for one to three hours or longer, if possible. The treatment can be brief, for example, once daily for three to twenty-one days, or can be longer, for example, once daily for three to six weeks.
